Biotech · Private company · New Rochelle, NY, US

New York/R&D/Ctr/Translational Med/Ther

Track this companyFree. Adds New York/R&D/Ctr/Translational Med/Ther to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards4

Exosome drug for tendinopathyFiscal year 2026 · $719.6KNIH RePORTER 5R44AG084503-03 · fetched Nov 12, 2026
Exosome drug for tendinopathyFiscal year 2025 · $719.6KNIH RePORTER 5R44AG084503-02 · fetched Nov 12, 2026
Exosome drug for tendinopathyFiscal year 2024 · $766.3KNIH RePORTER 1R44AG084503-01A1 · fetched Nov 12, 2026
miRNA drug for tendinopathyFiscal year 2024 · $560.1KNIH RePORTER 5R44AG081162-03 · fetched Nov 12, 2026